Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

1.

Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective.

Penault-Llorca F, Viale G.

Ann Oncol. 2012 Aug;23 Suppl 6:vi19-22. Review.

PMID:
23012297
[PubMed - indexed for MEDLINE]
Free Article
2.

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW.

Breast. 2012 Feb;21(1):50-7. doi: 10.1016/j.breast.2011.07.008. Epub 2011 Aug 23.

PMID:
21865043
[PubMed - indexed for MEDLINE]
3.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

PMID:
21762477
[PubMed - indexed for MEDLINE]
Free PMC Article
4.
5.

Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates.

Miyashita M, Ishida T, Ishida K, Tamaki K, Amari M, Watanabe M, Ohuchi N, Sasano H.

Virchows Arch. 2011 Jan;458(1):65-72. doi: 10.1007/s00428-010-1009-2. Epub 2010 Nov 21.

PMID:
21104095
[PubMed - indexed for MEDLINE]
6.

[Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].

Masuda N, Yasojima H, Mizutani M, Yamamura J.

Gan To Kagaku Ryoho. 2012 Apr;39(4):512-8. Japanese.

PMID:
22504674
[PubMed - indexed for MEDLINE]
7.

Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.

Nakagawa M, Bando Y, Nagao T, Takai C, Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Tangoku A, Sasa M.

Breast Cancer. 2012 Jan;19(1):54-9. doi: 10.1007/s12282-011-0265-6. Epub 2011 Apr 5.

PMID:
21465226
[PubMed - indexed for MEDLINE]
8.

Metastatic triple-negative breast cancer.

Rakha EA, Chan S.

Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600. doi: 10.1016/j.clon.2011.03.013. Epub 2011 Apr 23. Review.

PMID:
21524569
[PubMed - indexed for MEDLINE]
9.

Characteristics of triple-negative breast cancer.

de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC.

J Cancer Res Clin Oncol. 2011 Feb;137(2):183-92. doi: 10.1007/s00432-010-0957-x. Epub 2010 Nov 11. Review.

PMID:
21069385
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Triple-negative/basal-like breast cancer: review.

Rakha EA, Ellis IO.

Pathology. 2009 Jan;41(1):40-7. doi: 10.1080/00313020802563510. Review.

PMID:
19089739
[PubMed - indexed for MEDLINE]
11.

[Clinicopathologic features and prognosis of triple negative breast cancer].

Zhou T, Yang L, Ma GM, Li CX, Bai Y, Zhao JA, Wang XL, Geng CZ.

Zhonghua Yi Xue Za Zhi. 2009 Aug 25;89(32):2261-4. Chinese.

PMID:
20095338
[PubMed - indexed for MEDLINE]
12.

Triple-negative breast cancer: an unmet medical need.

Hudis CA, Gianni L.

Oncologist. 2011;16 Suppl 1:1-11. doi: 10.1634/theoncologist.2011-S1-01. Review.

PMID:
21278435
[PubMed - indexed for MEDLINE]
Free Article
13.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
[PubMed - indexed for MEDLINE]
14.

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.

Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen.

BMC Cancer. 2011 Jun 21;11:262. doi: 10.1186/1471-2407-11-262.

PMID:
21693047
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Treatment of triple negative breast cancer (TNBC): current options and future perspectives.

De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V, De Placido S.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S80-6. doi: 10.1016/S0305-7372(10)70025-6. Review.

PMID:
21129616
[PubMed - indexed for MEDLINE]
16.

Molecularly targeted therapies for metastatic triple-negative breast cancer.

Bayraktar S, Glück S.

Breast Cancer Res Treat. 2013 Feb;138(1):21-35. doi: 10.1007/s10549-013-2421-5. Epub 2013 Jan 29. Review.

PMID:
23358903
[PubMed - indexed for MEDLINE]
17.

Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.

Caldarella A, Puliti D, Crocetti E, Bianchi S, Vezzosi V, Apicella P, Biancalani M, Giannini A, Urso C, Zolfanelli F, Paci E.

J Cancer Res Clin Oncol. 2013 Feb;139(2):181-5. doi: 10.1007/s00432-012-1304-1. Epub 2012 Sep 9.

PMID:
22961208
[PubMed - indexed for MEDLINE]
18.

Triple-negative breast cancer: present challenges and new perspectives.

Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium.

Mol Oncol. 2010 Jun;4(3):209-29. doi: 10.1016/j.molonc.2010.04.006. Epub 2010 Apr 24. Review.

PMID:
20537966
[PubMed - indexed for MEDLINE]
Free Article
19.

[Triple-negative breast carcinoma--rewiev of current literature].

Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M.

Magy Onkol. 2010 Dec;54(4):325-35. doi: 10.1556/MOnkol.54.2010.4.6. Review. Hungarian.

PMID:
21163763
[PubMed - indexed for MEDLINE]
Free Article
20.

Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.

Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M.

BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403.

PMID:
24004841
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk